TD Cowen downgraded AN2 Therapeutics (ANTX) to Hold from Buy without a price target The Phase 2 EBO topline data in non-tuberculous mycobacterial saw no difference in culture conversion, the analyst tells investors in a research note. The firm says that while AN2 is evaluating restarting the Phase 3 EBO trial pending an FDA talk in the first half of 2025, it has “conservative expectations.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANTX: